Sodium-glucose cotransporter type 2 inhibitors (SGLT2i) were initially recommended as oral anti-diabetic drugs to treat type 2 diabetes (T2D), by inhibiting SGLT2 in proximal tubule and reduce renal reabsorption of sodium and glucose. While many clinical trials demonstrated the tremendous potential ...
Sodium-glucose cotransporter type 2 inhibitors (SGLT2i) were initially recommended as oral anti-diabetic drugs to treat type 2 diabetes (T2D), by inhibiting SGLT2 in proximal tubule and reduce renal reabsorption of sodium and glucose. While many clinical
It was unknown whether the benefits observed in EMPA-REG OUTCOME are specific to empagliflozin or are a class effect of SGLT2 inhibitors. However, following the results from EMPA-REG OUTCOME trial, the CANVAS Program reduced the risk of three-point MACE. As a result of these two trials, a...
1). This novel mechanism of action means SGLT2 inhibitors function independently of insulin levels, pancreatic function and degree of insulin resistance. Accordingly, this class of drug is expected to continue to maintain its potency as beta cell function deteriorate along with disease progression—a...
function, remodelling, and clinical outcomes among patients with diabetes following myocardial infarction and the influence of direct renin inhibition with ... AM Shah,SH Shin,M Takeuchi,... - 《European Journal of Heart Failure》 被引量: 105发表: 2014年 SGLT2 inhibitors: a promising new therap...
- 《Pharmacotherapy the Journal of Human Pharmacology & Drug Therapy》 被引量: 15发表: 2017年 Differentiating SGLT2 inhibitors in development for the treatment of type 2 diabetes mellitus Introduction: Sodium-glucose co-transporter-2 (SGLT2) inhibitors are a novel class of agents for the ...
Effect of SGLT2 inhibitors on cardiovascular outcomes across various patient populations J Am Coll Cardiol, 81 (2023), pp. 2377-2387 View PDFView articleGoogle Scholar 10 M. Vaduganathan, K.F. Docherty, B.L. Claggett, et al. SGLT-2 inhibitors in patients with heart failure: a comprehensiv...
Lack of evidence for a harmful effect of sodium-glucose co-transporter 2 (SGLT2) inhibitors on fracture risk among type 2 diabetes patients: a network and ... Lack of evidence for a harmful effect of sodium -glucose cotransporter 2 (SGLT 2) inhibitors on fracture risk among type 2 di- ...
The purpose of this study was to clarify the profiles of patients in whom SGLT-2 inhibitors are more likely to exert a renal protective effect in clinical practice. We retrospectively analyzed the medical record information of sixty-three type 2 diabetic patients (33 males, 30 females, average ...
Therefore, the combination of sodium-glucose transporter 2 inhibitors (SGLT2i) can likely improve or provide more cardiovascular benefits to patients with T1DM. METHODS. This study conducted a systematic review and meta-analysis of randomised controlled trials (RCTs) published in PubMed, Scopus, ...